Cover Image

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Nila Ganamurali, Sarvesh Sabarathinam
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Clinical Pharmacology in Drug Development
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management
by: Navodi Sandamini Jayathilaka, et al.
Published: (2025)

First‐in‐Human Study of Merotocin, a Short‐Acting Peptidic Oxytocin Receptor Agonist for Lactation Support
by: Yu Bagger, et al.
Published: (2025)

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist
by: Akihito Ogasawara, et al.
Published: (2024)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies
by: Andrew C. Vendel, et al.
Published: (2026)

Computer‐Aided Algorithmic Approaches to Drug Development for Multi‐Mutant HIV‐1 Reverse Transcriptase
by: Akmal Zubair, et al.
Published: (2025)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
by: Wei Zhu, et al.
Published: (2026)

First‐In‐Human Study to Assess the Pharmacokinetics and Safety of DS‐6016a After Single Subcutaneous Injection in Healthy Japanese Adults
by: Kei Okita, et al.
Published: (2026)

Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers
by: Eugenio Mercuri, et al.
Published: (2026)

Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions
by: Sudershan Kumar, et al.
Published: (2026)

Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
by: Ronilda D'Cunha, et al.
Published: (2026)

Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial
by: Gregory M. Sullivan, et al.
Published: (2026)

Issue Information
Published: (2026)

A Human Mass Balance and Metabolism Study of [ 14 C]‐Ubrogepant in Healthy Male Adults
by: Ramesh R. Boinpally, et al.
Published: (2026)

Issue Information
Published: (2026)

A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers
by: Angela Jeong, et al.
Published: (2026)

Impact of Sampling Window Variability on Pharmacokinetic Parameters Estimated by Non‐Compartmental Analysis: Case Studies of Various Types of Drugs
by: Kyosuke Takahashi, et al.
Published: (2026)

Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers
by: Bruce L Daugherty, et al.
Published: (2026)

Safety, Tolerability, and Pharmacokinetics of Mufemilast, a PDE4 Inhibitor, in Healthy Participants: A First‐in‐Human Phase 1 Study
by: Xiuqi Li, et al.
Published: (2026)

Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers
by: Pan Luo, et al.
Published: (2026)

Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open‐Label, Parallel‐Group Study
by: Vincent Chow, et al.
Published: (2026)

LP‐001, a Novel Long‐Acting EPO‐Fc Fusion Protein: A Phase I Dose‐Escalation Study of Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects
by: Jie Yang, et al.
Published: (2026)

Pharmacokinetics of Aztreonam–Avibactam After Single‐ and Multiple‐Dose Administration: A Phase 1, Open‐Label Study in Healthy Chinese Participants and Ethnic Comparison with Non‐Chinese Participants
by: Jingjing Wang, et al.
Published: (2026)

The Work Behind the First Dose: How Early Clinical Studies Shape the Course of Drug Development
by: Amalia M. Issa
Published: (2026)

Pharmacokinetics, Bioequivalence, and Safety of Diclofenac Sodium Sustained‐Release Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
by: Biao Sun, et al.
Published: (2026)

From Reflection to Acceleration: Clinical Pharmacology’s 2025 Lessons and 2026 Opportunities
by: Amalia M. Issa
Published: (2026)

Clinical Significance of IL‐4 and IL‐21 Concurrent Elevation in Predicting Disease Activity Score and Antihistamine Treatment Response in Chronic Spontaneous Urticaria
by: Shining Wang, et al.
Published: (2026)

Issue Information
Published: (2026)

Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [ 14 C]Xevinapant, a Potent, Oral, Small‐Molecule IAP Inhibitor
by: Annick Menetrey, et al.
Published: (2026)

Ethnic Bridging of Votoplam, a HTT Gene Splicing Modifier, Using Pharmacokinetic Comparison Between Caucasian and Japanese Subjects
by: Lucy Lee, et al.
Published: (2026)

What Makes an Early‐Phase Study Worth Publishing? A View from the Editor's Desk
by: Amalia M. Issa
Published: (2026)

Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open‐Label, Four‐Period Crossover Study Under Fasting and Fed Conditions
by: Jingyan Wang, et al.
Published: (2026)

Pharmacokinetic Comparison Between a Fixed‐Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components
by: Seungri Lee, et al.
Published: (2026)

Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity
by: Amalia M. Issa
Published: (2026)

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
by: Gerard Greig, et al.
Published: (2026)

Pharmacokinetic Interaction Among Amlodipine, Losartan, and Chlorthalidone after a Single Oral Administration in Healthy Male Subjects
by: Seol Ju Moon, et al.
Published: (2026)

Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects
by: Hongcheng Li, et al.
Published: (2026)

Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy Adults
by: Thomas M. Polasek, et al.
Published: (2026)

Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy Volunteers
by: Dietmar Schwab, et al.
Published: (2026)

Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
by: Aravind Mittur, et al.
Published: (2026)

Issue Information
Published: (2026)